Zenazocine

Zenazocine

Zenazocine
Systematic (IUPAC) name
1-[(1S,9R)-4-hydroxy-1,10,13-trimethyl-10-azatricyclo[7.3.1.02,7]trideca-2,4,6-trien-13-yl]-6-methyl-3-heptanone
Clinical data
Legal status
  • Non-regulated
Identifiers
CAS number
ATC code None
PubChem
ChemSpider
Chemical data
Formula C23H35NO2 
Mol. mass 357.530 g/mol

Zenazocine (INN; WIN-43,964) is an opioid analgesic of the benzomorphan family which made it to phase II clinical trials before development was ultimately halted and it was never marketed.[1][2] It acts as a partial agonist of the μ- and δ-opioid receptors, with less intrinsic activity at the former receptor and more at the latter receptor (hence, it behaves more antagonistically at the former and more agonistically at the latter), and produces antinociceptive effects in animal studies.[1]

See also

References

  1. ^ a b Ward, S. J.; Pierson, A. K.; Michne, W. F. (1985). "Pharmacological profiles of tonazocine (Win 42156) and zenazocine (Win 42964)". Neuropeptides 5 (4–6): 375–378.  
  2. ^ Cotton, R.; James, R. (1985). "Chapter 3. Analgesics, Opioids and Opioid Receptors". In Bailey, D. M. Annual Reports in Medicinal Chemistry 20. Academic Press. pp. 21–30.